Amendments to the Claims:

1. (Original) A pharmaceutical composition comprising:

a) an ionogenic surfactant;

b) a metal chelating complex comprising a metal and a monodentate, bidentate, or polydentate ligand that exhibits affinity for hydrogen ion;

c) a solvent; and,

d) a pharmaceutically acceptable carrier.

2. (Original) The pharmaceutical composition of claim 1, wherein said composition comprises by weight about 0.1-15% ionogenic surfactant, about 1-30% metal chelating complex, and about 0.5-95% solvent.

3. (Original) The pharmaceutical composition claim of 1, wherein said metal is selected from the group consisting of copper, zinc, mercury, chromium, manganese, nickel, cadmium, arsenic, cobalt, aluminum, lead, selenium, platinum, gold, titanium, tin, and combinations thereof.

4. (Original) The pharmaceutical composition of claim 1, wherein the monodentate, bidentate, or polydentate ligand is selected from the group consisting of anions of natural amino acids, iminodiacetic acids, nitriletriacetitic acids, derivatives of iminodiacetic acids comprising a carbon-substitution in the α-position to the carboxylic group and amino acid residue fragments containing no aminocarboxylic group, derivatives of nitriletriacetic acids comprising a carbon-substitution in the α-position to the carboxylic group and amino acid residue fragments containing no aminocarboxylic group, alkylenediaminopolyacetic acid, derivatives of polyalkylenepolyaminopolyacetitc acids comprising a carbon-substitution in the α-position to the carboxylic group and amino acid residue fragments containing no aminocarboxylic group, derivatives of ω-phosphoncarboxylic, derivatives of ethylenediphosphontetrapropionic acids, derivatives of ethelynetetra(thioacetic), derivatives of diethylenetrithiodiacetic acids, monoamine complexones in which carboxylic groups are replaced by phosphonic groups, and mixtures thereof.

5. (Original) The pharmaceutical composition of claim 1, wherein the metal chelating complex comprises at least one amino acid selected from the group consisting of isoleucine, phenylalanine, leucine, lysine, methionine, threonine, tryptophan, valine, alanine, glycine, arginine, and histidine.

6. (Original) The pharmaceutical composition of claim 1, wherein the metal chelating complex comprises a glycinatecopper halide complex.

7. (Original) The pharmaceutical composition of claim 1, wherein the metal chelating complex comprises an ethylenediaminotetraacetate zinc (Zn-EDTA) complex.

8. (Canceled)

9. (Canceled)

10. (Currently amended) The pharmaceutical composition of claim 1, wherein the ionogenic surfactant is selected from the group consisting of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride, cetylbenzyldimethylammonium chloride, cetylpyridinium bromide (CPB), ~~cetyltrimethylammkonium~~ cetyltrimethylammonium bromide (CTAB), cetyldimethylethylammonium bromide, cetyltributylphosphonium bromide, dodecyltrimethylammonium bromide, and tetradecyltrimethylammonium bromide.

11. (Original) The pharmaceutical composition of claim 10, wherein the ionogenic surfactant is CPC.

12. (Original) The pharmaceutical composition of claim 1, wherein said solvent is an aliphatic alcohol.

13. (Original) The pharmaceutical composition of claim 12, wherein said aliphatic alcohol is isopropanol.

14. (Currently amended) ~~A~~ The pharmaceutical composition of claim 1, wherein the ionogenic surfactant comprises CPC, the metal chelating complex comprises Zn-EDTA, and the solvent comprises isopropanol. ~~comprising CPC, Zn-EDTA, isoproranol, and a pharmaceutically acceptable carrier.~~

15. (Currently amended) The pharmaceutical composition of claim 14, wherein said composition comprises by weight about 0.2% CPC, about 1% Zn-EDTA, and about 9.8% ~~isoproranol~~ isopropanol.

16. (Currently amended) The pharmaceutical composition of claim 14, wherein said composition comprises by weight about 0.02% CPC, about 1% Zn-EDTA, and about 9.8% ~~isoproranol~~ isopropanol.

17. (Currently amended) The pharmaceutical composition of claim 14, wherein said composition comprises by weight about 0.002% CPC, about 1% Zn-EDTA, and about 9.8% ~~isoproranol~~ isopropanol.

18. (Original) The pharmaceutical composition of claim 1 further comprising at least one additional pharmaceutical composition.

19. (Original) The pharmaceutical composition of claim 18, wherein said at least one additional pharmaceutical composition is an antimicrobial composition.

20. (Original) The pharmaceutical composition of claim 19, wherein said antimicrobial composition is an antifungal composition.

21. (Canceled)

22. (Currently amended) The pharmaceutical composition of claim 1, ~~as in any one of claims 1-21,~~ wherein said pharmaceutical composition is formulated for topical administration, oral administration, or intravenous administration.

23. (Canceled)

24. (Canceled)

25. (Currently amended) A method for treating or preventing an infection caused by a pathogen in a subject, said method comprising administering to said subject an effective amount of the pharmaceutical composition of claim 1 ~~according to any one of claims 1-24~~.

26. (Original) The method of claim 25, wherein said pathogen is selected from the group consisting of a bacterium, a virus, and a fungus.

27-36. (Canceled)

37. (Currently amended) A method for treating or preventing dandruff, acne, or dermatitis in a subject comprising administering to said subject an effective amount of the pharmaceutical composition of claim 1 ~~according to any one of claims 1-24~~.

38-40. (Canceled)

41. (Original) The method of claim 25 further comprising administration of at least one additional pharmaceutical composition.

42-45. (Canceled)

46. (Currently amended) The method of claim 25 ~~according to any one of claims 22-45~~, wherein said pharmaceutical composition is administered orally, topically, or intravenously.

47. (Canceled)

48. (Canceled)